Topotecan Pharmacokinetic Characterization Study

Summary

Topotecan Pharmacokinetic Characterization Study is a clinical trial^[1].

Key Facts

• Topotecan Pharmacokinetic Characterization Study is in the country of United States^[2].
• Topotecan Pharmacokinetic Characterization Study's instance of is recorded as clinical trial^[3].
• Topotecan Pharmacokinetic Characterization Study's start time is recorded as +2006-09-12T00:00:00Z^[4].
• Topotecan Pharmacokinetic Characterization Study's end time is recorded as +2007-08-09T00:00:00Z^[5].
• Topotecan Pharmacokinetic Characterization Study's sponsor is recorded as GSK^[6].
• Topotecan Pharmacokinetic Characterization Study's main subject is recorded as bronchitis^[7].
• Topotecan Pharmacokinetic Characterization Study's main subject is recorded as cancer^[8].
• Topotecan Pharmacokinetic Characterization Study's main subject is recorded as pharmacokinetics^[9].
• Topotecan Pharmacokinetic Characterization Study's number of participants is recorded as {'unit': '1', 'amount': '+15'}^[10].
• Topotecan Pharmacokinetic Characterization Study's title is recorded as A Phase I Study to Characterize the Pharmacokinetics of 4 mg/m2 Weekly Intravenous Topotecan in Patients With Cancer^[11].
• Topotecan Pharmacokinetic Characterization Study's minimum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+18'}^[12].
• Topotecan Pharmacokinetic Characterization Study's ClinicalTrials.gov ID is recorded as NCT00361803^[13].
• Topotecan Pharmacokinetic Characterization Study's research intervention is recorded as topotecan^[14].
• Topotecan Pharmacokinetic Characterization Study's clinical trial phase is recorded as phase I clinical trial^[15].
• Topotecan Pharmacokinetic Characterization Study's research site is recorded as GSK^[16].
• Topotecan Pharmacokinetic Characterization Study's research subject recruitment status is recorded as completed^[17].
• Topotecan Pharmacokinetic Characterization Study's study type is recorded as interventional study^[18].